View more in
Cancer

Phase III Results Support BMS’ CAR-T Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

biospace.com
 2021-06-10

Cover picture for the articlePhoto courtesy of Bristol Myers Squibb. Topline results from a Phase III study show Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) significantly improved survival and response better than standard-of-care salvage therapy with high-dose chemotherapy and transplant in patients with relapsed/refractory large-B cell lymphoma. The study therapy – Breyanzi – is a...

www.biospace.com

Comments / 0

Comments / 0